JP2009532452A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009532452A5 JP2009532452A5 JP2009503667A JP2009503667A JP2009532452A5 JP 2009532452 A5 JP2009532452 A5 JP 2009532452A5 JP 2009503667 A JP2009503667 A JP 2009503667A JP 2009503667 A JP2009503667 A JP 2009503667A JP 2009532452 A5 JP2009532452 A5 JP 2009532452A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently
- membered
- tautomer
- stereoisomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 43
- 125000000623 heterocyclic group Chemical group 0.000 claims 18
- -1 octahydroindolidinyl Chemical group 0.000 claims 18
- 229910052760 oxygen Inorganic materials 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 15
- 229910052736 halogen Inorganic materials 0.000 claims 14
- 150000002367 halogens Chemical class 0.000 claims 14
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 14
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 239000001257 hydrogen Substances 0.000 claims 13
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 13
- 125000005842 heteroatom Chemical group 0.000 claims 12
- 229920006395 saturated elastomer Polymers 0.000 claims 12
- 229910052717 sulfur Inorganic materials 0.000 claims 12
- 150000002431 hydrogen Chemical class 0.000 claims 11
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 5
- 125000005843 halogen group Chemical group 0.000 claims 5
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 3
- 125000000168 pyrrolyl group Chemical group 0.000 claims 3
- 229930195734 saturated hydrocarbon Natural products 0.000 claims 3
- 229930195735 unsaturated hydrocarbon Natural products 0.000 claims 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 2
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 claims 2
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 claims 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 1
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 1
- 125000006719 (C6-C10) aryl (C1-C6) alkyl group Chemical group 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010057430 Retinal injury Diseases 0.000 claims 1
- 206010038997 Retroviral infections Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 125000003725 azepanyl group Chemical group 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 125000005959 diazepanyl group Chemical group 0.000 claims 1
- 125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 claims 1
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000005061 octahydroisoindolyl group Chemical group C1(NCC2CCCCC12)* 0.000 claims 1
- 125000005961 oxazepanyl group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 1
- 239000002534 radiation-sensitizing agent Substances 0.000 claims 1
- 230000009759 skin aging Effects 0.000 claims 1
- 230000037380 skin damage Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0606663A GB0606663D0 (en) | 2006-04-03 | 2006-04-03 | Therapeutic compounds |
| GB0615907A GB0615907D0 (en) | 2006-08-11 | 2006-08-11 | Therapeutic Compounds |
| GBGB0700432.8A GB0700432D0 (en) | 2007-01-10 | 2007-01-10 | Therapeutic compounds |
| PCT/GB2007/050177 WO2007113596A1 (en) | 2006-04-03 | 2007-04-02 | Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009532452A JP2009532452A (ja) | 2009-09-10 |
| JP2009532452A5 true JP2009532452A5 (enExample) | 2010-08-12 |
| JP4611441B2 JP4611441B2 (ja) | 2011-01-12 |
Family
ID=38441875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009503667A Active JP4611441B2 (ja) | 2006-04-03 | 2007-04-02 | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール及びベンゾトリアゾール誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20090275619A1 (enExample) |
| EP (1) | EP2007733B1 (enExample) |
| JP (1) | JP4611441B2 (enExample) |
| AU (1) | AU2007232297B2 (enExample) |
| CA (1) | CA2647545C (enExample) |
| WO (1) | WO2007113596A1 (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0610680D0 (en) * | 2006-05-31 | 2006-07-12 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
| EP3536690A1 (en) * | 2007-01-10 | 2019-09-11 | MSD Italia S.r.l. | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors |
| US20080293771A1 (en) * | 2007-05-24 | 2008-11-27 | Wyeth | Azacyclylbenzamide derivatives as histamine-3 antagonists |
| KR20100102609A (ko) * | 2007-11-12 | 2010-09-24 | 바이파 사이언스 인코포레이티드 | Ｐａｒｐ 억제제를 단독으로 사용하거나 항종양제와 병용하여 유방암을 치료하는 방법 |
| JP5989965B2 (ja) * | 2008-01-08 | 2016-09-07 | メルク シャープ エンド ドーム リミテッド | ２−｛４−［（３ｓ）−ピペリジン−３−イル］フェニル｝−２ｈ−インダゾール−７−カルボキサミドの薬学的に許容される塩 |
| EP2247600A4 (en) * | 2008-02-06 | 2011-09-14 | Biomarin Pharm Inc | INHIBITORS BASED ON BENZOXAZOLE-CARBOXAMIDE COMPOUNDS OF POLY (ADP-RIBOSE) POLYMERASE (PARP) ACTIVITY |
| GB0804755D0 (en) | 2008-03-14 | 2008-04-16 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| ITFI20090005A1 (it) * | 2009-01-19 | 2010-07-20 | Alberto Chiarugi | Formulazioni farmaceutiche per indurre immunosoppressione attraverso l'inibizione del fenomeno dell'epitope spreading e loro uso. |
| ES2759751T3 (es) * | 2009-07-14 | 2020-05-12 | Nerviano Medical Sciences Srl | 3-oxo-2,3-dihidro-1H-isoindol-4-carboxamidas |
| US8765972B2 (en) | 2009-07-14 | 2014-07-01 | Nerviano Medical Sciences S.R.L. | 3-oxo-2,3-dihydro-1H-isoindole-4-carboxamides with selective PARP-1 inhibition |
| US8425662B2 (en) | 2010-04-02 | 2013-04-23 | Battelle Memorial Institute | Methods for associating or dissociating guest materials with a metal organic framework, systems for associating or dissociating guest materials within a series of metal organic frameworks, and gas separation assemblies |
| WO2011141909A2 (en) | 2010-05-10 | 2011-11-17 | Radikal Therapeutics Inc. | Lipoic acid and nitroxide derivatives and uses thereof |
| WO2012006958A1 (en) * | 2010-07-14 | 2012-01-19 | Zhejiang Beta Pharma Inc. | Amids substituted indazole derivativees as ploy(adp-ribose)polymerase inhibitors |
| CN103052633B (zh) * | 2010-07-14 | 2016-03-23 | 贝达药业股份有限公司 | 酰胺基取代的吲唑衍生物类聚(adp-核糖)聚合酶抑制剂 |
| EP2642998B1 (en) | 2010-11-24 | 2020-09-16 | The Trustees of Columbia University in the City of New York | A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease |
| WO2013014038A1 (en) * | 2011-07-26 | 2013-01-31 | Nerviano Medical Sciences S.R.L. | 3-oxo-2,3-dihydro-1h-indazole-4-carboxamide derivatives as parp-1 inhibitors |
| JP5468119B2 (ja) * | 2011-09-26 | 2014-04-09 | 日東電工株式会社 | 増強された太陽光集光効率のための高蛍光性かつ光安定性の発色団 |
| JP2013084952A (ja) | 2011-10-05 | 2013-05-09 | Nitto Denko Corp | 太陽光捕集効率を向上させるための、感圧接着剤層を含む波長変換膜 |
| TW201331192A (zh) * | 2012-01-17 | 2013-08-01 | Zhejiang Beta Pharma Inc | 醯胺基取代的吲唑衍生物類聚（ａｄｐ－核糖）聚合酶抑制劑 |
| US9333202B2 (en) | 2012-05-01 | 2016-05-10 | The Trustees Of Columbia University In The City Of New York | Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease |
| US9580407B2 (en) | 2012-12-07 | 2017-02-28 | Merck Sharp & Dohme Corp. | Regioselective N-2 arylation of indazoles |
| US9944644B2 (en) | 2013-03-14 | 2018-04-17 | The Trustees Of Columbia University In The City Of New York | Octahydropyrrolopyrroles their preparation and use |
| US10273243B2 (en) | 2013-03-14 | 2019-04-30 | The Trustees Of Columbia University In The City Of New York | 4-phenylpiperidines, their preparation and use |
| ES2700541T3 (es) | 2013-03-14 | 2019-02-18 | Univ Columbia | Octahidrociclopentapirroles, su preparación y uso |
| WO2014151959A1 (en) | 2013-03-14 | 2014-09-25 | The Trustees Of Columbia University In The City Of New York | N-alkyl-2-phenoxyethanamines, their preparation and use |
| CA2916298C (en) | 2013-06-26 | 2021-10-12 | Abbvie Inc. | Primary carboxamides as btk inhibitors |
| WO2015053402A1 (ja) * | 2013-10-11 | 2015-04-16 | 国立大学法人東京医科歯科大学 | 脊髄小脳変性症を予防又は治療するための薬剤 |
| JP6676541B2 (ja) | 2014-04-30 | 2020-04-08 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | 置換された４−フェニルピペリジン、その調製及び使用 |
| JP6878316B2 (ja) * | 2015-06-19 | 2021-05-26 | ノバルティス アーゲー | Ｓｈｐ２の活性を阻害するための化合物および組成物 |
| AU2016296905B2 (en) | 2015-07-23 | 2018-07-05 | Centre National De La Recherche Scientifique | Use of a combination of Dbait molecule and parp inhibitors to treat cancer |
| EP3411373A1 (en) | 2016-02-05 | 2018-12-12 | Syngenta Participations AG | Pesticidally active heterocyclic derivatives with sulphur containing substituents |
| EP3478286B1 (en) | 2016-06-29 | 2024-01-03 | Tesaro, Inc. | Methods of treating ovarian cancer |
| IL322013A (en) | 2016-07-29 | 2025-09-01 | Janssen Pharmaceutica Nv | Niraparib or its salts for use in the treatment of prostate cancer |
| WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
| TWI761476B (zh) | 2017-03-27 | 2022-04-21 | 美商提薩羅有限公司 | 尼拉帕尼(niraparib)組合物 |
| CN110300587B (zh) * | 2017-04-04 | 2023-07-18 | 康姆芘法思催化剂股份有限公司 | 氘代(s)-2-(4-(哌啶-3-基)苯基)-2h-吲唑-7-甲酰胺 |
| CN110753684A (zh) | 2017-04-24 | 2020-02-04 | 特沙诺有限公司 | 尼拉帕利的制造方法 |
| EP3621592A4 (en) | 2017-05-09 | 2021-03-17 | Tesaro, Inc. | COMBINATION THERAPIES FOR TREATMENT OF CANCER |
| WO2018208123A1 (ko) * | 2017-05-12 | 2018-11-15 | 한국화학연구원 | 신규한 피페리딘-2,6-디온 유도체 및 이의 용도 |
| KR102014478B1 (ko) * | 2017-05-12 | 2019-08-26 | 한국화학연구원 | 신규한 피페리딘-2,6-디온 유도체 및 이의 용도 |
| WO2018213732A1 (en) | 2017-05-18 | 2018-11-22 | Tesaro, Inc. | Combination therapies for treating cancer |
| EP3668857B1 (en) | 2017-08-14 | 2023-07-05 | Teva Pharmaceuticals International GmbH | Processes for the preparation of niraparib and intermediates thereof |
| WO2019067634A1 (en) | 2017-09-26 | 2019-04-04 | Tesaro, Inc. | Niraparib formulations |
| CA3076515A1 (en) | 2017-09-30 | 2019-04-04 | Tesaro, Inc. | Combination therapies for treating cancer |
| SG11202002499TA (en) | 2017-10-06 | 2020-04-29 | Tesaro Inc | Combination therapies and uses thereof |
| US20210030735A1 (en) | 2018-02-05 | 2021-02-04 | Tesaro, Inc. | Pediatric niraparib formulations and pediatric treatment methods |
| JP7534218B2 (ja) | 2018-03-13 | 2024-08-14 | ヴァレリオ・セラピューティクス | がんの治療における獲得耐性に対抗するｄｂａｉｔ分子 |
| EP3774734A1 (en) | 2018-03-29 | 2021-02-17 | Elex Biotech, Inc. | Compounds for treatment of cardiac arrhythmias and heart failure |
| US20210030680A1 (en) * | 2018-04-13 | 2021-02-04 | The Board Of Regents Of University Of Texas System | Nanoparticle compositions and methods of use of parp inhibitor for treatment of cancer |
| US12297184B2 (en) | 2018-10-03 | 2025-05-13 | Tesaro, Inc. | Niraparib salts |
| KR102735378B1 (ko) * | 2018-11-09 | 2024-11-27 | 한국화학연구원 | 신규한 피페리딘-2,6-디온 유도체 및 이의 용도 |
| MX2021015499A (es) * | 2019-06-27 | 2022-04-20 | Biogen Ma Inc | Derivados de 2h-indazol y su uso en el tratamiento de enfermedades. |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| EP4112049A4 (en) * | 2020-02-24 | 2024-07-24 | Fukang (Shanghai) Health Technology Co., Ltd. | ANTI-CORONAVIRUS APPLICATION OF POLY ADP-RIBOSE POLYMERASE INHIBITOR |
| WO2024261243A1 (en) | 2023-06-21 | 2024-12-26 | Hemispherian As | Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL123147A (en) * | 1995-08-02 | 2004-02-19 | Univ Newcastle Ventures Ltd | Benzamide imidazole - 4 carboxamide and their use |
| CN1331682A (zh) * | 1998-11-03 | 2002-01-16 | 巴斯福股份公司 | 取代的2－苯基苯并咪唑类,其制备和用途 |
| HRP20010451A2 (en) * | 1998-11-17 | 2003-04-30 | Basf Ag | 2-phenylbenzimidazoles and 2-phenylindoles, and production and use thereof |
| IL143303A0 (en) * | 1998-11-27 | 2002-04-21 | Basf Ag | Substituted benzimidazoles and their use as parp inhibitors |
| DE19918211A1 (de) * | 1999-04-22 | 2000-10-26 | Basf Ag | Cycloalkylsubstituierte Benzimidazole, deren Herstellung und Anwendung |
| DE19920936A1 (de) * | 1999-05-07 | 2000-11-09 | Basf Ag | Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung |
| ATE372337T1 (de) * | 2000-02-01 | 2007-09-15 | Abbott Gmbh & Co Kg | Heterozyklische verbindungen und deren anwendung als parp-inhibitoren |
| DE10022925A1 (de) * | 2000-05-11 | 2001-11-15 | Basf Ag | Substituierte Indole als PARP-Inhibitoren |
| JP2003005323A (ja) * | 2001-06-20 | 2003-01-08 | Konica Corp | 熱現像写真感光材料及び画像形成方法 |
| EP1585726A1 (en) * | 2003-01-06 | 2005-10-19 | Eli Lilly And Company | Fused heterocyclic derivatives as ppar modulators |
| JP2007520471A (ja) * | 2003-12-22 | 2007-07-26 | イーライ リリー アンド カンパニー | Ｐｐａｒ受容体調節物質としての二環式誘導体 |
| KR100876520B1 (ko) * | 2004-09-22 | 2008-12-31 | 화이자 인코포레이티드 | 폴리(ａｄｐ-리보오스) 폴리머라제 억제제의 제조 방법 |
| TWI375673B (en) * | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
| WO2006110683A1 (en) * | 2005-04-11 | 2006-10-19 | Abbott Laboratories | 2-substituted-1h-benzimidazole-4-carboxamides are parp inhibitors |
| CN101316834A (zh) * | 2005-09-29 | 2008-12-03 | 艾博特公司 | 在2位取代有苯基的1h-苯并咪唑-4-甲酰胺是强效parp抑制剂 |
| US7462724B2 (en) * | 2005-11-15 | 2008-12-09 | Abbott Laboratories | Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors |
| CN101511821B (zh) * | 2006-05-02 | 2013-07-17 | Abbvie公司 | 取代的1h-苯并咪唑-4-羧酰胺类化合物是有效的parp抑制剂 |
| EP3536690A1 (en) * | 2007-01-10 | 2019-09-11 | MSD Italia S.r.l. | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors |
-
2007
- 2007-04-02 AU AU2007232297A patent/AU2007232297B2/en active Active
- 2007-04-02 JP JP2009503667A patent/JP4611441B2/ja active Active
- 2007-04-02 CA CA2647545A patent/CA2647545C/en active Active
- 2007-04-02 WO PCT/GB2007/050177 patent/WO2007113596A1/en not_active Ceased
- 2007-04-02 US US12/225,857 patent/US20090275619A1/en not_active Abandoned
- 2007-04-02 EP EP07733600.6A patent/EP2007733B1/en active Active
-
2011
- 2011-04-21 US US13/091,427 patent/US20110201657A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009532452A5 (enExample) | ||
| AU2021202962B2 (en) | Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity | |
| EP4139286B1 (en) | Substituted aminothiazoles as dgkzeta inhibitors for immune activation | |
| AU2014364744B2 (en) | Novel carboxamides, method for the production thereof, pharmaceutical preparations comprising them, and use thereof for producing medicaments | |
| JP2010536842A5 (enExample) | ||
| AU2009260726B2 (en) | S1P1 receptor agonists and use thereof | |
| US9073875B2 (en) | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase | |
| DK2694510T3 (en) | IMIDAZOPYRIDAZINER AS AKT kinase inhibitors | |
| ES2967119T3 (es) | Compuestos inhibidores de metaloenzimas | |
| ES2934227T3 (es) | Inhibidores de isoindolinona de la interacción mdm2-p53 con actividad anticancerígena | |
| JP2011513475A5 (enExample) | ||
| JP2009538897A5 (enExample) | ||
| JP2013544261A5 (enExample) | ||
| AU2016322848B2 (en) | 1-phenylpyrrolidin-2-one derivatives as perk inhibitors | |
| EP3013815B1 (en) | Carbazole carboxamide compounds useful as kinase inhibitors | |
| US10023576B2 (en) | Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors | |
| AU2019364352A1 (en) | 5-membered heteroaryl carboxamide compounds for treatment of HBV | |
| KR20180088466A (ko) | 인플루엔자 바이러스 복제 저해제, 활용 방법 및 그 용도 | |
| US20240124422A1 (en) | Mutant pi3k-alpha inhibitors and their use as pharmaceuticals | |
| JP2013508382A5 (enExample) | ||
| JP2013505930A5 (enExample) | ||
| JP2013501785A (ja) | 結核阻害剤としてのピリミジン化合物 | |
| WO2016064957A1 (en) | Bicyclic heteroaryl amine compounds as pi3k inhibitors | |
| CA3024482A1 (en) | Macrocyclic indole derivatives | |
| IL297305A (en) | The heteroaryl carboxamide compounds of pentadentate compounds for the treatment of HBV |